ubmslateEN-logo-ubm

EN Mobile Logo

Search form

Topics:

Beyond Basal Insulin in Type 2 Diabetes

Beyond Basal Insulin in Type 2 Diabetes

  • Beyond Basal Insulin in Type 2 Diabetes. from ADA Scientific Sessions
  • Insulin Degludec/Liraglutide vs. Insulin Glargine. Abstract link.
  • Patients with T2DM treated with insulin degludec/liraglutide have a greater chance of reaching glycemic targets.
  • Insulin degludec/liraglutide led to better glycemic control.
  • Faster-acting Insulin Aspart. Abstract link.
  • Faster-acting insulin aspart improves postprandial glycemic control in uncontrolled T2DM.
  • Faster aspart effectively improved 1-hour postprandial plasma glucose control.
  • Faster-acting Insulin vs. Basal Insulin. Abstract link.
  • Adding faster-acting insulin aspart to basal insulin significantly improved glycemic control.
  • Faster aspart in a basal-bonus regimen provided superior glycemic control versus basal insulin only.
  • Insulin Glargine/Lixisenatide vs. Insulin Glargine. Abstract link.
  • A fixed-ratio combination of insulin glargine/lixisenatide is more effective and safer than insulin glargine in patients with T2DM.
  • After a 6-week run-in phase, insulin glargine was introduced or optimized.
  • Glargine/lixisenatide showed superior glycemic control to insulin glargine.

Several studies presented at the 2016 American Diabetes Association annual meeting dealt with going beyond basal insulin treatments for type 2 diabetes mellitus (DM) patients. Here are the highlights from four abstracts on treatment intensification options.

Add new comment

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.